MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease

被引:136
作者
Kumar, Subodh [1 ]
Vijayan, Murali [1 ]
Reddy, P. Hemachandra [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Biomarker Unit,Garrison Inst Aging, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA
[4] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Neurol, Lubbock, TX 79430 USA
[5] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Speech Language & Hearing Sci, Lubbock, TX 79430 USA
[6] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Publ Hlth, Lubbock, TX 79430 USA
关键词
AMYLOID-BETA; EXPRESSION; DIAGNOSIS; PLASMA; MIRNA; RISK;
D O I
10.1093/hmg/ddx267
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of our study was to identify microRNAs (miRNAs) as early detectable peripheral biomarkers in Alzheimer's disease (AD). To achieve our objective, we assessed miRNAs in serum samples from AD patients and Mild cognitive impairment (MCI) subjects relative to healthy controls. We used Affymetrix microarray analysis and validated differentially expressed miRNAs using qRT-PCR. We further validated miRNA data using AD postmortem brains, amyloid precursor protein transgenic mice and AD cell lines. We identified a gradual upregulation of four miRNAs: miR-455-3p, miR-4668-5p, miR-36133p and miR-4674. A fifth miRNA, mir-6722, was down-regulated in persons with AD and mild cognitive impairment compared with controls. Validation analysis by qRT-PCR showed significant upregulation of only miR-455-3p (P = 0.007) and miR-46685p (P = 0.016) in AD patients compared with healthy controls. Furthermore, qRT-PCR analysis of the AD postmortem brains with different Braak stages also showed upregulation of miR-455-3p (P = 0.016). However, receiver operating characteristic curves (ROC) curve analysis revealed a significant area under curve (AUC) value only for miR-455-3p in the serum (AUROC = 0.79; P = 0.015) and brains (AUROC = 0.86; P = 0.016) of AD patients. Expression analysis of amyloid precursor protein transgenic mice also revealed high level of mmu-miR-455-3p (P = 0.004) in the cerebral cortex (AD-affected) region of brain and low in the non-affected area, i.e. cerebellum. Furthermore, human and mouse neuroblastoma cells treated with the amyloid- b(1-42) peptide also showed a similarly higher expression of miR-455-3p. Functional analysis of differentially expressed miRNAs via the miR-path indicated that miR-455-3p was associated in the regulation of several biological pathways. Genes associated with these pathways were found to have a crucial role in AD pathogenesis. An increase in miR-455-3p expression found in AD patients and Ab pathologies unveiled its biomarker characteristics and a precise role in AD pathogenesis.
引用
收藏
页码:3808 / 3822
页数:15
相关论文
共 50 条
  • [41] Long non-coding RNA NEAT1 promotes pulmonary fibrosis by regulating the microRNA-455-3p/SMAD3 axis
    Liu, Yuan
    Lu, Fu-Ai
    Wang, Le
    Wang, Yong-Fu
    Wu, Chun-Feng
    MOLECULAR MEDICINE REPORTS, 2021, 23 (03)
  • [42] Biomarker Profile in Peripheral Blood Cells Related to Alzheimer's Disease
    Lomi, Mirko
    Geraci, Filippo
    Del Seppia, Cristina
    Dolciotti, Cristina
    Del Carratore, Renata
    Bongioanni, Paolo
    MOLECULAR NEUROBIOLOGY, 2025,
  • [43] P50: A candidate ERP biomarker of prodromal Alzheimer's disease
    Green, Deborah L.
    Payne, Lisa
    Polikar, Robi
    Moberg, Paul J.
    Wolk, David A.
    Kounios, John
    BRAIN RESEARCH, 2015, 1624 : 390 - 397
  • [44] BACE: Therapeutic target and potential biomarker for Alzheimer's disease
    Evin, Genevieve
    Barakat, Adel
    Masters, Colin L.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (12) : 1923 - 1926
  • [45] BACE1 as a Potential Biomarker for Alzheimer's Disease
    Decourt, Boris
    Sabbagh, Marwan N.
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 24 : 53 - 59
  • [46] Pentosidine determination in CSF: a potential biomarker of Alzheimer's disease?
    Monacelli, Fiammetta
    Borghi, Roberta
    Pacini, Davide
    Serrati, Carlo
    Traverso, Nicola
    Odetti, Patrizio
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (01) : 117 - 120
  • [47] Insights on benzodiazepines' potential in Alzheimer's disease
    Al-Kuraishy, Hayder M.
    Al-Gareeb, Ali I.
    Alsayegh, Abdulrahman A.
    Abusudah, Wafaa Fouzi
    Almohmadi, Najlaa Hamed
    Eldahshan, Omayma A.
    Ahmed, Eman A.
    Batiha, Gaber El -Saber
    LIFE SCIENCES, 2023, 320
  • [48] Central nervous system and peripheral inflammatory processes in Alzheimer's disease: biomarker profiling approach
    Delaby, Constance
    Gabelle, Audrey
    Blum, David
    Schraen-Maschke, Susanna
    Moulinier, Amandine
    Boulanghien, Justine
    Severac, Dany
    Buee, Luc
    Reme, Thierry
    Lehmann, Sylvain
    FRONTIERS IN NEUROLOGY, 2015, 6
  • [49] Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations
    Cosin-Tomas, Marta
    Antonell, Anna
    Llado, Albert
    Alcolea, Daniel
    Fortea, Juan
    Ezquerra, Mario
    Lleo, Albert
    Jose Marti, Maria
    Pallas, Merce
    Sanchez-Valle, Raquel
    Luis Molinuevo, Jose
    Sanfeliu, Coral
    Kaliman, Perla
    MOLECULAR NEUROBIOLOGY, 2017, 54 (07) : 5550 - 5562
  • [50] 3α,5α-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia
    Charles D. Smith
    David R. Wekstein
    William R. Markesbery
    Cheryl A. Frye
    Psychopharmacology, 2006, 186 : 481 - 485